Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDActive Not Recruiting
NCT06724809Phase 3Updated Dec 19, 2025
Sponsor: Alexion Pharmaceuticals, Inc.
NMOSD · Neuromyelitis Optica Spectrum Disorders
China
C.Difficile Observational StudyCompleted
NCT06277999N/AUpdated Dec 19, 2025
Sponsor: AstraZeneca
Clostridium Infections
United States
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial InfarctionRecruiting
NCT05764057Phase 3Updated Dec 19, 2025
Sponsor: Assistance Publique - Hôpitaux de Paris
AMI · STEMI · NSTEMI · Left Ventricular Dysfunction
France
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and BreathlessnessRecruiting
NCT06110403Phase 1, Phase 2Updated Dec 18, 2025
Sponsor: University Hospital, Lille
Copd
France
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityCompleted
NCT06579092Phase 2Updated Dec 18, 2025
Sponsor: AstraZeneca
Obesity or Overweight
United States, Australia, Canada, Germany, Japan +2 more
A Real-world, Multi-center, Prospective, Observational Study for PNH in ChinaCompleted
NCT06154512N/AUpdated Dec 18, 2025
Sponsor: AstraZeneca
Paroxysmal Nocturnal Hemoglobinuria
China
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLCRecruiting
NCT06102057Phase 2Updated Dec 17, 2025
Sponsor: TheraOp
Stage III Non-small Cell Lung Cancer · Locally Advanced · Unresectable
Germany, Switzerland
Real-World Treatment Study of Soliris (Eculizumab)Completed
NCT06448715N/AUpdated Dec 17, 2025
Sponsor: AstraZeneca
Observational
South Korea
ROSE for Improved Molecular Marker Testing Via EBUSEnrolling By Invitation
NCT04945317NAUpdated Dec 17, 2025
Sponsor: Johns Hopkins University
Non-small Cell Lung Cancer (NSCLC)
United States
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled HypertensionCompleted
NCT06336356Phase 2Updated Dec 17, 2025
Sponsor: AstraZeneca
Uncontrolled Hypertension
United States
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCTerminated
NCT04765709Phase 2Updated Dec 16, 2025
Sponsor: Mario Negri Institute for Pharmacological Research
Non-small Cell Lung Cancer Stage III
France, Italy, Spain
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruiting
NCT06757647Phase 2Updated Dec 16, 2025
Sponsor: Seema Bhat
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
United States
This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLECompleted
NCT06698900N/AUpdated Dec 16, 2025
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
Brazil
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe AsthmaCompleted
NCT05274815Phase 3Updated Dec 11, 2025
Sponsor: AstraZeneca
Asthma
United States, Argentina, Belgium, Bulgaria, France +6 more
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy ParticipantsCompleted
NCT06502379Phase 1Updated Dec 11, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Active Not Recruiting
NCT01844986Phase 3Updated Dec 10, 2025
Sponsor: AstraZeneca
Newly Diagnosed · Advanced Ovarian Cancer · FIGO Stage III-IV · BRCA Mutation
United States, Australia, Brazil, Canada, China +10 more
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompleted
NCT02328014Phase 1, Phase 2Updated Dec 9, 2025
Sponsor: Acerta Pharma BV
Non-Hodgkins Lymphoma · Multiple Myeloma · B-All
United States
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruiting
NCT04430452Phase 2Updated Dec 8, 2025
Sponsor: Mary Feng, MD
Advanced Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v8 · Stage IIIA Hepatocellular Carcinoma AJCC v8 · Stage IIIB Hepatocellular Carcinoma AJCC v8
United States
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive Not Recruiting
NCT04538742Phase 1, Phase 2Updated Dec 8, 2025
Sponsor: AstraZeneca
Metastatic Breast Cancer
United States, Australia, Brazil, Canada, France +10 more
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in ChinaCompleted
NCT05876351Phase 3Updated Dec 8, 2025
Sponsor: Alexion Pharmaceuticals, Inc.
Atypical Hemolytic Uremic
China
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)Active Not Recruiting
NCT04238637Phase 2Updated Dec 5, 2025
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Intrahepatic Cholangiocarcinoma
Germany
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaCompleted
NCT03381183Phase 1Updated Dec 5, 2025
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck · Metastatic Squamous Cell Carcinoma · Oral Cavity Squamous Cell Carcinoma
United States
ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyActive Not Recruiting
NCT05065554Phase 2Updated Dec 5, 2025
Sponsor: Shayna Sarosiek, MD
IgM MGUS · Waldenstrom Macroglobulinemia · Neuropathy;Peripheral
United States
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese ParticipantsCompleted
NCT06715670Phase 1Updated Dec 4, 2025
Sponsor: AstraZeneca
Liver Cirrhosis
United States
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal ImpairmentCompleted
NCT06661733Phase 1Updated Dec 3, 2025
Sponsor: AstraZeneca
Renal Impairment
Bulgaria

Previous page Next page